All-cause mortality in treated HIV-infected adults with CD4 >/=500/mm3 compared with the general population: evidence from a large European observational cohort collaboration, Int J Epidemiol, vol.41, pp.433-478, 2012. ,
Life expectancy of HIV-positive adults: a review, Sex Health, vol.8, pp.526-559, 2011. ,
All-cause and liver-related mortality in HIV positive subjects compared to the general population: differences by HCV co-infection, J Hepatol, vol.57, pp.743-51, 2012. ,
Meta-analysis: increased mortality associated with hepatitis C in HIV-infected persons is unrelated to HIV disease progression, Clin Infect Dis, vol.49, pp.1605-1620, 2009. ,
Causes of death among HIV-infected patients in France in 2010 (national survey): trends since, AIDS, vol.28, pp.1181-91, 2000. ,
Liver-related deaths in HIVinfected patients between, 1995. ,
URL : https://hal.archives-ouvertes.fr/hal-01939337
, Mortalite 2010 survey, HIV Med, vol.16, pp.230-239, 2015.
The French national prospective cohort of patients co-infected with HIV and HCV (ANRS CO13 HEPAVIH): early findings, BMC Infect Dis, vol.10, p.303, 2006. ,
URL : https://hal.archives-ouvertes.fr/pasteur-01070193
Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection, N Engl J Med, vol.361, pp.580-93, 2009. ,
Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel, AIDS, vol.21, pp.1073-89, 2007. ,
Response to pegylated interferon plus ribavirin among HIV/hepatitis C virus-coinfected patients with compensated liver cirrhosis, Clin Infect Dis, vol.55, pp.1719-1745, 2012. ,
Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial, Lancet Infect Dis, vol.13, pp.597-605, 2013. ,
Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis, Gastroenterology, vol.147, pp.132-174, 2014. ,
URL : https://hal.archives-ouvertes.fr/inserm-01057763
Telaprevir for HIV/hepatitis C viruscoinfected patients failing treatment with pegylated interferon/ribavirin (ANRS HC26 TelapreVIH): an open-label, single-arm, phase 2 trial, Clin Infect Dis, vol.59, pp.1768-76, 2014. ,
URL : https://hal.archives-ouvertes.fr/hal-01118447
Triple therapy with boceprevir or telaprevir in a European cohort of cirrhotic HIV/HCV genotype 1-coinfected patients, Liver Int, vol.35, pp.2090-2099, 2015. ,
HCV viral load at baseline and at week 4 of telaprevir/boceprevir based triple therapies are associated with virological outcome in HIV/hepatitis C co-infected patients, J Clin Virol, vol.73, pp.32-37, 2015. ,
Favourable SVR12 rates with boceprevir or telaprevir triple therapy in HIV/HCV coinfected patients, Neth J Med, vol.73, pp.324-354, 2015. ,
Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection, JAMA, vol.312, pp.353-61, 2014. ,
Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, openlabel, non-randomised, phase 3 study, Lancet, vol.385, pp.1098-106, 2015. ,
Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1, N Engl J Med, vol.373, pp.714-739, 2015. ,
Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1, N Engl J Med, vol.373, pp.705-718, 2015. ,
paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial, JAMA, vol.313, pp.1223-1254, 2015. ,
Factors associated with guidelinebased hepatitis C virus (HCV) treatment initiation in HIV/HCV-coinfected patients: role of comorbidities and physicians' perceptions, HIV Med, vol.14, pp.430-436, 2013. ,
, American Association for the Study of Liver Diseases/Infectious Diseases Society of America HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus, Hepatology, vol.62, pp.932-54, 2015.
, European Association for the Study of the Liver. EASL recommendations on treatment of Hepatitis C 2015, J Hepatol, vol.63, pp.199-236, 2015.
Recommandations AFEF sur la prise en charge des hépatites virales C. Paris: Association Française pour l'Etude du Foie, 2015. ,
Sofosbuvir for chronic hepatitis C virus infection genotype 1-4 in patients coinfected with HIV, J Acquir Immune Defic Syndr, vol.68, pp.543-552, 2015. ,
Daclatasvir plus sofosbuvir for HCV infection, N Engl J Med, vol.370, pp.1560-1561, 2014. ,
Safety and efficacy of simeprevir/sofosbuvir in hepatitis C-infected patients with compensated and decompensated cirrhosis, Hepatology, vol.62, pp.715-740, 2015. ,
Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease, Gastroenterology, vol.149, pp.649-59, 2015. ,
Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis, Jama, vol.308, pp.2584-93, 2012. ,
Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/ HCV, JAMA, vol.308, pp.370-378, 2012. ,
Mortality in HIV-hepatitis C coinfected patients in Canada compared to the general Canadian population, AIDS, vol.28, pp.1957-65, 2014. ,
Effects of sustained viral response in patients with HIV and chronic hepatitis C and nonadvanced liver fibrosis, J Acquir Immune Defic Syndr, vol.66, pp.280-287, 2014. ,
,
, Virologie: S. Fourati
,
, Virologie: C. Tamalet)
, Virologie: C. Le Pendeven
, Toulouse (Maladies Infectieuses et Tropicales: B. Marchou; Hépato-gastro-entérologie
, Virologie: F. Larroquette
, DAAs in HIV/HCV-Coinfected Cirrhotic Patients ? CID, vol.2016, p.769
, Virologie: C. Partouche)
,
, Virologie: Y. Baazia
, Virologie: F. Nicot
, Virologie: G. Alexandre
,
, Virologie: P. Palmer)
, Maladies Infectieuses et Tropicales
,
, Maladies Infectieuses: D. Vittecoq
, Maladies Infectieuses et Tropicales: O. Lortholary, C. Duvivier, M. Shoai-Tehrani: Virologie: A. Mélard)
,
, Virologie: P. Trimoulet, S. Reigadas
,
, Virologie: P. Trimoulet, S. Reigadas
,
, Virologie: F. Guitard)
, Virologie: C. Deback)
,
, Virologie: A. Rodallec
, Virologie: T. T. Le-Thi
, Simonet-Lann, D. CroisierBertin
, Perpignan (Maladies infectieuses et tropicales: H. Aumaître)
Médecine interne, maladies infectieuses et immunologie clinique ,
,